Corcept (CORT) Q4 Earnings Beat Estimates, Korlym Sales Grow

Corcept Therapeutics Incorporated (CORT) reported fourth-quarter 2023 earnings of 28 cents per share, which beat the Zacks Consensus Estimate of 25 cents. The company reported earnings of 14 cents per share in the year-ago quarter.Revenues increased 31% year over year to $135.4 million. The figure beat the Zacks Consensus Estimate of$130 million. The top line solely comprises product sales of Cushing’s syndrome drug, Korlym.Quarter in DetailRevenues from Korlym met our model estimate of $135.4 million.Rese ...